These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 30962289)

  • 1. Mechanism of Reductive Metabolism and Chiral Inversion of Proton Pump Inhibitors.
    Tang C; Chen Z; Dai X; Zhu W; Zhong D; Chen X
    Drug Metab Dispos; 2019 Jun; 47(6):657-664. PubMed ID: 30962289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereoselective disposition of proton pump inhibitors.
    Andersson T; Weidolf L
    Clin Drug Investig; 2008; 28(5):263-79. PubMed ID: 18407713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
    Li XQ; Andersson TB; Ahlström M; Weidolf L
    Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of proton pump inhibitors in children.
    Litalien C; Théorêt Y; Faure C
    Clin Pharmacokinet; 2005; 44(5):441-66. PubMed ID: 15871633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restoration of acid secretion following treatment with proton pump inhibitors.
    Shin JM; Sachs G
    Gastroenterology; 2002 Nov; 123(5):1588-97. PubMed ID: 12404233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know.
    Robinson M; Horn J
    Drugs; 2003; 63(24):2739-54. PubMed ID: 14664653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality.
    Kromer W
    Scand J Gastroenterol Suppl; 2001; (234):3-9. PubMed ID: 11768559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
    de Korwin JD; Ducrotté P; Vallot T
    Presse Med; 2004 Jun; 33(11):746-54. PubMed ID: 15257232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
    Caro JJ; Salas M; Ward A
    Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
    Welage LS; Berardi RR
    J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel.
    Chen CH; Yang JC; Uang YS; Lin CJ
    Biopharm Drug Dispos; 2012 Jul; 33(5):278-83. PubMed ID: 22623337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doubly charged trimeric cluster ions: effective in mutual chiral recognition of tadalafil and three proton pump inhibitors.
    Wang L; Chai Y; Zhu W; Pan Y; Sun C; Zeng S
    Analyst; 2017 Feb; 142(5):745-751. PubMed ID: 28197557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
    Zvyaga T; Chang SY; Chen C; Yang Z; Vuppugalla R; Hurley J; Thorndike D; Wagner A; Chimalakonda A; Rodrigues AD
    Drug Metab Dispos; 2012 Sep; 40(9):1698-711. PubMed ID: 22648560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole.
    Qi F; Zhu L; Li N; Ge T; Xu G; Liao S
    Int J Antimicrob Agents; 2017 Apr; 49(4):403-409. PubMed ID: 28159656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
    Ogilvie BW; Yerino P; Kazmi F; Buckley DB; Rostami-Hodjegan A; Paris BL; Toren P; Parkinson A
    Drug Metab Dispos; 2011 Nov; 39(11):2020-33. PubMed ID: 21795468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formulary management of proton pump inhibitors.
    Byrne MF; Murray FE
    Pharmacoeconomics; 1999 Sep; 16(3):225-46. PubMed ID: 10558037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes.
    Katsuki H; Hamada A; Nakamura C; Arimori K; Nakano M
    Eur J Clin Pharmacol; 2001 Dec; 57(10):709-15. PubMed ID: 11829200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of proton pump inhibitors on the pharmacokinetics of voriconazole in vitro and in vivo.
    Yan M; Wu ZF; Tang D; Wang F; Xiao YW; Xu P; Zhang BK; Liu YP; Xiang DX; Banh HL
    Biomed Pharmacother; 2018 Dec; 108():60-64. PubMed ID: 30216801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enantioselective disposition of lansoprazole and rabeprazole in human plasma.
    Miura M
    Yakugaku Zasshi; 2006 Jun; 126(6):395-402. PubMed ID: 16755125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
    Klotz U
    Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.